What a PVR Study Shows About Pulmonary Valve Replacement

PVR study most commonly refers to research on pulmonary valve replacement, a procedure that has become one of the most actively investigated areas in congenital heart disease. The field has exploded with data over the past two decades as growing numbers of patients who had childhood repairs for conditions like tetralogy of Fallot reach adulthood needing a functioning pulmonary valve. But PVR is also an abbreviation used in two entirely different medical contexts: pulse volume recording for diagnosing peripheral artery disease, and post-void residual measurement in urology. This article focuses primarily on pulmonary valve replacement research, where the stakes and the volume of published studies are highest, then covers what you should know about the other two uses.

Why Pulmonary Valve Replacement Gets So Much Attention

Tetralogy of Fallot is the most common cyanotic congenital heart defect, and surgical repair in infancy has been standard for decades. The repair saves lives, but it often damages or removes the pulmonary valve entirely, leaving the patient with pulmonary regurgitation, meaning blood leaks backward through the valve after each heartbeat. That leak is the single most important long-term consequence of the original repair, and it progressively strains the right ventricle over years.¹ Eventually the right side of the heart enlarges, its pumping efficiency drops, and patients develop exercise intolerance, abnormal heart rhythms, or heart failure. Replacing the pulmonary valve can reverse much of that damage, but the central question in PVR research is when to do it and how.

Updated clinical practice guidelines published in 2026 by the Society of Thoracic Surgeons and partner organizations reflect how rapidly the evidence base has shifted. Compared with earlier recommendations, the latest guidelines place greater emphasis on symptoms in both children and adults, on ventricular volume measurements in adults, and on the role of invasive electrophysiology testing before proceeding with valve replacement.² These shifts are driven by a flood of imaging, exercise-testing, and outcomes data accumulated over the past five years.

Imaging and Timing Thresholds

Cardiac MRI is the workhorse for deciding whether a patient needs PVR. The key measurement is how large the right ventricle has become relative to the patient’s body size, expressed as an indexed end-diastolic volume. An influential study in Circulation identified a threshold: when that volume stays below about 160 mL per square meter of body surface area before surgery, the right ventricle can shrink back to a normal size afterward. Above that threshold, the ventricle still gets smaller after PVR, but it may not fully normalize.³ A more recent study refined this further, identifying an echocardiographic inflection point in right ventricular area at one year after surgery: patients who started with a volume index above 150 mL/m² had slower and less complete recovery compared to those below that mark.⁴

Beyond simple volume, MRI-derived strain measurements can add precision. Strain captures how well the heart muscle is actually contracting, and certain patterns of reduced strain have been shown to predict when a patient has crossed the line into needing intervention, even before the ventricle has ballooned to traditional cutoff sizes.⁵

Exercise testing adds another layer. Cardiopulmonary exercise testing measures peak oxygen uptake, which reflects the whole cardiopulmonary system’s fitness. In one large study, peak oxygen uptake was the strongest independent predictor of early surgical mortality after PVR, outperforming other measures on multivariable analysis.⁶ In other words, patients who are already in poor aerobic condition before surgery face higher risk. This makes the case for not waiting too long, but it also creates a practical tension: operate early enough that the patient is still fit, yet not so early that you replace a valve years before it was truly needed, setting the clock on prosthetic valve durability.

Who Benefits Most From PVR in Exercise Capacity

One of the puzzles in PVR research is that not everyone’s exercise tolerance improves afterward. A Korean study tracked patients before and after valve replacement and found that those who started with the worst exercise capacity (a predicted peak oxygen uptake around 60% of normal) were the ones who gained the most.⁷ Patients who already had reasonably preserved fitness before surgery actually showed a decline in exercise capacity afterward. The researchers found that changes in right ventricular pumping function correlated tightly with changes in exercise performance, but the direction of the benefit depended on where you started. This is clinically important: if your exercise tolerance is still good, PVR may not make you feel meaningfully better on a treadmill, even though it could protect the ventricle structurally.

What Happens to the Left Side of the Heart

PVR is performed on the right side of the heart, but the left ventricle is affected too. The two ventricles share the septum and sit in the same pericardial sac, so when the right ventricle is chronically dilated, it pushes the septum leftward and physically compresses the left ventricle. Researchers call this adverse ventricular interaction, and it means left ventricular pumping can suffer even though the left side has no intrinsic disease.

After PVR, the left ventricle’s pumping fraction improved significantly in patients who started with reduced left ventricular function, rising from roughly 38% to 47% in one cohort, while patients who started with normal left-sided function showed little change.⁸ Separate research on transcatheter valve replacement confirmed that left ventricular filling, shape symmetry, and strain all improved progressively over the first year, with some measures continuing to get better at intermediate follow-up.⁹ This left-sided recovery is an underappreciated benefit of timely PVR. When patients or cardiologists are on the fence about whether to proceed, it is worth recognizing that both ventricles stand to gain.

Surgical Versus Transcatheter Valve Replacement

PVR can be performed in the operating room with open-heart surgery or in a catheterization lab via a catheter threaded through a vein. The transcatheter approach avoids cracking the chest open and placing the patient on a heart-lung machine, which carries obvious appeal, especially for people who have already had one or more open-heart surgeries. The data from multiple analyses comparing the two approaches show a consistent pattern of trade-offs rather than a clear winner.

An analysis of over 11,000 hospitalizations for PVR in adults with congenital heart disease found that the transcatheter group had a dramatically shorter hospital stay (about 3 days versus nearly 10 days) and far fewer major complications. Surgical patients had more than five times the odds of kidney injury and infection, and were vastly more likely to need mechanical circulatory support during their stay.¹⁰ Two meta-analyses found that transcatheter PVR was associated with lower overall mortality during follow-up, though short-term (30-day) mortality was statistically similar between the groups.¹¹¹²

The catch is endocarditis, a serious infection of the valve itself. Both meta-analyses found that transcatheter PVR carried roughly three to five times higher odds of endocarditis during follow-up compared with surgical replacement. This risk is not trivial and has become one of the most closely watched complications in the field.

The Endocarditis Problem After Transcatheter PVR

Endocarditis after transcatheter PVR has proven stubbornly common. A large multicenter study reported a cumulative incidence of about 9.5% at five years and roughly 17% at eight years, amounting to about 2.2 cases per 100 patient-years.¹³ Risk factors included younger age, a prior episode of endocarditis, and a higher leftover pressure gradient across the valve after the procedure. Another study found that children aged 12 or under at implant and patients with a post-implant gradient of 15 mmHg or higher were at roughly two to three times the risk.¹⁴

Immune status matters too. In a single-center study, patients with weakened immune systems had about five times the hazard of developing endocarditis compared with immunocompetent patients, and their five-year freedom from infection was only about 64% versus 87%.¹⁵ When it comes to valve brand, data comparing the Melody valve with the SAPIEN valve showed that the SAPIEN had a much lower rate of endocarditis, around 0.2 per 100 patient-years versus 5.5 for the Melody.¹⁶ The reasons are debated but may relate to differences in valve material and frame design. This endocarditis risk is a major reason why transcatheter PVR hasn’t simply replaced surgery across the board.

Long-Term Durability and Reintervention

Any bioprosthetic valve eventually wears out. For surgical bioprostheses placed in the pulmonary position, younger patients face faster deterioration. A study of porcine valves showed that freedom from structural valve breakdown at ten years was about 77% overall but significantly worse in patients under 20.¹⁷ A more recent comparison found that pericardial surgical valves had a five-year dysfunction rate of about 39% versus 17% for porcine valves, though the types of dysfunction differed: pericardial valves tended to leak, while porcine valves developed higher gradients over time.¹⁸

For transcatheter valves, ten-year follow-up from the original Melody investigational cohort showed freedom from reintervention of about 60% and freedom from death of about 90%.¹⁹ The SAPIEN valve fared somewhat better, with ten-year freedom from a second valve replacement of around 82% versus about 50% for the Melody.²⁰ When a transcatheter or surgical bioprosthesis does fail, a valve-in-valve procedure, placing a new transcatheter valve inside the old one, is increasingly used and has been reported even in unusual clinical settings like carcinoid heart disease.²¹

Newer devices are expanding who can receive a transcatheter valve. The Harmony valve was designed specifically for patients with native, or non-conduit, right ventricular outflow tracts, which are larger and more irregular than conduits and historically couldn’t accommodate a catheter-based valve. Three-year results from the early feasibility study showed stable valve function in most patients, with no deaths and only two explants, though two patients developed tissue growth inside the valve that needed a valve-in-valve fix.²² The Venus P-valve, designed for similar anatomy, has shown procedural success above 95% and durable function out to five years, with recovery of right ventricular size within six to twelve months.²³

Predictors of Bad Outcomes After PVR

Even though PVR is generally safe, a subset of patients remain at elevated risk for death or dangerous heart rhythms afterward. The INDICATOR cohort, a large multicenter registry, has produced some of the strongest data on this. Before PVR, patients with a right ventricular ejection fraction below 40%, a high ratio of heart muscle mass to volume, or age 28 or older at the time of surgery all had significantly higher hazards for the combined outcome of death or sustained ventricular tachycardia.²⁴ In an analysis of the broader repaired tetralogy of Fallot population regardless of whether they had PVR, high right ventricular mass-to-volume ratio, reduced left ventricular function, and a history of abnormal atrial rhythms were all independent predictors of death or sustained ventricular tachycardia.²⁵

Age alone has a striking impact. A UK national audit found that patients undergoing PVR after age 35 had a ten-year mortality of about 10%, compared with just over 1% for those who had the procedure before 35.²⁶ And the electrical conduction system matters: after PVR, patients whose QRS duration on an electrocardiogram remained at or above 180 milliseconds, or who showed no shortening at all, were at higher risk for ventricular tachycardia and warranted consideration for a defibrillator.²⁷

Quality of Life and Costs

Hard endpoints like survival and reintervention rates dominate PVR research, but how patients feel day to day matters just as much to them. A cross-sectional study of adults with congenital heart disease who had any valve replacement found that they scored significantly lower than the general population on general health, vitality, and social functioning domains of a quality-of-life questionnaire. The strongest predictor of poor quality of life across every domain was functional class: patients who were more symptomatic scored worse, underscoring the importance of not delaying intervention until function has deteriorated substantially.²⁸ A separate quasi-meta-analysis found that some quality-of-life measures do improve after both surgical and transcatheter PVR, though the evidence base, particularly for the transcatheter approach, remains thin.²⁹

On the cost side, the two approaches have surprisingly similar upfront price tags. A pediatric database analysis found no significant difference in adjusted short-term costs, roughly $50,000 for each, though the composition of charges differed: transcatheter cases had higher device costs while surgical cases racked up more pharmacy, lab, and ancillary charges.³⁰ When projected out to five years, however, the transcatheter approach’s higher reintervention rate tipped costs upward to roughly $65,000 versus about $57,000 for surgery.³¹ These numbers are from U.S. datasets; in lower-income healthcare systems the calculus can differ dramatically. A cost-utility analysis from an Indonesian perspective found that transcatheter PVR, while yielding more quality-adjusted life years, was not cost-effective relative to surgical replacement at prevailing economic thresholds.³²

The Other PVR Studies You Might Encounter

If you searched for “PVR study” and your context is vascular or urological rather than cardiac, here is what the abbreviation means in those fields.

In vascular medicine, PVR stands for pulse volume recording, a bedside test used since the early 1970s to detect peripheral artery disease. Blood pressure cuffs are placed at different levels of the arm or leg and inflated slightly; the instrument records the volume change in the limb with each pulse. The shape of the waveform tells clinicians whether blood flow at that level is normal, mildly impaired, or severely blocked.³³ Recent work has explored using pulse volume recordings at the forefoot level in diabetic patients, where standard ankle-level measurements can be unreliable because calcified arteries give falsely normal readings. One study found that a quantitative metric derived from the forefoot PVR waveform had strong accuracy for detecting any level of peripheral artery disease in diabetic feet.³⁴

In urology, PVR means post-void residual, the volume of urine left in the bladder after you finish urinating. It is typically measured with a portable ultrasound scanner and is one of the first tests ordered when someone has trouble emptying their bladder. A population-based study of randomly selected men found that the typical post-void residual was only about 10 mL, but men with enlarged prostates were roughly 2.5 times more likely to have a residual above 50 mL, and those with elevated residuals at baseline were about three times as likely to end up in acute urinary retention needing a catheter over the next few years.³⁵ Beyond prostate conditions, post-void residual monitoring is used after surgery under anesthesia, after childbirth, and in neurological conditions like multiple sclerosis that affect bladder control. A comprehensive review noted that routine PVR measurement reduces unnecessary catheterizations and the urinary infections that follow.³⁶